Clinical Efficacy of Minimally Invasive Pulmonary Surfactant Delivery Technique on Respiratory Distress Syndrome in Premature Infants*1

LAI Yi-yu, TIAN Xiao-hua, CHEN Rui-qi, YUAN Fei-fei, WEI Jian-wei, KONG Juan, ZHONG Xin-qi

PDF(1930 KB)
KANGGANRAN YAOXUE
KANGGANRAN YAOXUE ›› 2021, Vol. 18 ›› Issue (11) : 1703-1709. DOI: 10.13493/j.issn.1672-7878.2021.11-041

Clinical Efficacy of Minimally Invasive Pulmonary Surfactant Delivery Technique on Respiratory Distress Syndrome in Premature Infants*1

  • LAI Yi-yu*2, TIAN Xiao-hua, CHEN Rui-qi, YUAN Fei-fei, WEI Jian-wei, KONG Juan, ZHONG Xin-qi*3
Author information +
History +

Abstract

Objective: To investigate the clinical efficacy, complications and neurological prognosis of pulmonary surfactant (PS) in the treatment of respiratory distress syndrome in premature infants. Methods: 92 neonates hospitalized in the NICU（Neonatal intensive Care Unit） of the Third Affiliated Hospital of Guangzhou Medical University from August 2018 to July 2019 were selected and divided into endotracheal intubation group and minimally invasive group based on PS administration method. The differences in clinical efficacy, complications and neurodevelopmental assessment results at 35 weeks of gestational age were compared between the two groups. Results: The rate of invasive ventilation at 72 h in the minimally invasive group was lower than that in the endotracheal intubation group (2.27% vs 14.03%, P= 0.0396,), and the incidence of mild intracranial hemorrhage in the minimally invasive group was lower than that in the endotracheal intubation group (16.28% vs 36.73%, P< 0.05). There were no statistically significant differences in adverse events such as bradycardia and decreased blood oxygen saturation between the two groups, as well as in clinical efficacy indicators such as re-use of PS during hospitalization, duration of non-invasive positive airway pressure ventilation and total duration of oxygen use (P> 0.05). There was no significant difference between the two groups in the proportion of common premature complications such as bronchopulmonary dysplasia, retinopathy of prematurity, patent ductus arteriosus with hemodynamic significance and neurobehavioral score < 35 points during hospitalization (P> 0.05). Conclusions: Compared with traditional administration, minimally invasive pulmonary surfactant administration could reduce the rate of mechanical ventilation within 72 h and the incidence of mild intracranial hemorrhage during hospitalization of premature infants, and has no significant effect on short-term clinical efficacy, common complications of premature infants and short-term neurological outcomes.

Key words

premature infants / minimally invasive pulmonary surfactant therapy / clinical efficacy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
LAI Yi-yu, TIAN Xiao-hua, CHEN Rui-qi, YUAN Fei-fei, WEI Jian-wei, KONG Juan, ZHONG Xin-qi. Clinical Efficacy of Minimally Invasive Pulmonary Surfactant Delivery Technique on Respiratory Distress Syndrome in Premature Infants*1. KANGGANRAN YAOXUE. 2021, 18(11): 1703-1709 https://doi.org/10.13493/j.issn.1672-7878.2021.11-041

References

[1] Dargaville PA, Ali SKM, Jackson HD, et al. Impact of minimally invasive surfactant therapy in preterm infants at 29-32 weeks gestation[J]. Neonatology, 2018, 113(1): 7-14.
[2] Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome - 2016 update[J]. Neonatology, 2017, 111(2): 107-125.
[3] McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus:the need for disease staging[J]. Arch Dis Child Fetal Neonatal Ed, 2007, 92(6): F 424-F 427.
[4] Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants[J]. Cochrane Database Syst Rev, 2008(1): CD 003951.
[5] 邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[M].4 版.北京:人民卫生出版社,2011.
[6] 鲍秀兰. 新生儿行为能力和测查方法[J].实用诊断与治疗杂志,2003,17(6):441-443.
[7] Coalson JJ.Pathology of new bronchopulmonary dysplasia[J]. Semin Neonatol, 2003, 8(1): 73-81.
[8] 刘慧强,童笑梅,韩彤妍,等.微创应用肺表面活性物质治疗早产儿呼吸窘迫综合征的多中心临床研究[J].中华儿科杂志,2020,58(5):374-380.
[9] Dargaville PA, Aiyappan A, De Paoli AG, ,et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure[J]. Arch Dis Child Fetal Neonatal Ed. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure[J]. Arch Dis Child Fetal Neonatal Ed, 2013, 98(2): F 122-F 126.
[10] Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome - 2019 update[J]. Neonatology, 2019, 115(4): 432-450.
[11] Göpel W, Kribs A, Härtel C, et al. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants[J]. Acta Paediatr, 2015, 104(3): 241-246.
[12] Aldana-Aguirre JC, Pinto M, Featherstone RM, ,et al. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome:a systematic review. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome:a systematic review and meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2017, 102(1): F 17-F 23.
[13] 荣箫,周伟,赵小朋,等.微创肺表面活性物质治疗在新生儿呼吸窘迫综合征中的疗效与安全性[J].中华实用儿科临床杂志,2018,33(14):1071-1074.
[14] Kribs A, Härtel C, Kattner E, et al. Surfactant without intubation in preterm infants with respiratory distress:first multi-center data[J]. Klin Padiatr, 2010, 222(1): 13-17.
[15] Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV):an open-label,randomised,controlled trial[J]. Lancet, 2011, 378(9803): 1627-1634.
[16] Stark A, Dammann C, Nielsen HC, et al. A pathogenic relationship of bronchopulmonary dysplasia and retinopathy of prematurity?A review of angiogenic mediators in both diseases[J]. Front Pediatr, 2018, 6: 125.
[17] Kribs A,Roll C,Göpel W, et al. Nonintubated surfactant application vs conventional therapy in extremely preterm infants:a randomized clinical trial[J]. JAMA Pediatr, 2015, 169(8): 723-730.
[18] Härtel C,Paul P,Hanke K, et al. Less invasive surfactant administration and complications of preterm birth[J]. Sci Rep, 2018, 8: 8333.
[19] Teig N,Weitkämper A,Rothermel J,et al. Observational study on less invasive surfactant administration (LISA) in preterm Infants29 weeks——short and long-term outcomes[J]. Z Geburtshilfe Neonatol, 2015, 219(6): 266-273.
[20] Herting E, Kribs A, Härtel C, et al. Two-year outcome data suggest that less invasive surfactant administration (LISA) is safe.Results from the follow-up of the randomized controlled AMV (avoid mechanical ventilation) study[J]. Eur J Pediatr, 2020, 179(8): 1309-1313.
[21] Porath M, Korp L, Wendrich D, et al. Surfactant in spontaneous breathing with nCPAP:neurodevelopmental outcome at early school age of infants ≤ 27 weeks[J]. Acta Paediatr, 2011, 100(3): 352-359.
PDF(1930 KB)

125

Accesses

0

Citation

Detail
Sections
Recommended

/

〈 〉